Dr. Hurvitz on the Findings of DESTINY-Breast01 in HER2+ Metastatic Breast Cancer

Supplements and Featured Publications, Recent Advances in HER2+ Breast Cancer, Volume 1, Issue 1

In Partnership With:

Partner | Cancer Centers | <b>UCLA Health Jonsson Comprehensive Cancer Center</b>

Sarah A. Hurvitz, MD, medical oncologist, medical director, Clinical Research Unit for University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the findings in the DESTINY-Breast01 trial of patients with HER2-positive metastatic breast cancer.

Sarah A. Hurvitz, MD, medical oncologist, medical director, Clinical Research Unit for University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the findings in the DESTINY-Breast01 trial of patients with HER2-positive metastatic breast cancer.

This was a single-arm, phase II study in which patients with HER2-positive metastatic breast cancer received fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201). Patients enrolled on the trial received a median of 6 prior lines of therapy.

Results showed that fam-trastuzumab deruxtecan-nxki led to an overall response rate of 60.3% and the median progressive-free survival was 16.4 months.

In reflecting on the future treatment of patients with HER2-positive metastatic breast cancer, Hurvitz stressed the importance of ongoing phase III randomized trials to regularize the future treatment of fam-trastuzumab deruxtecan-nxki.